Mutant having uracil phosphoribosyl transferase activity
CA 2292882 C · Owner: Erbs, Philippe · Inventors: Jund, Richard; Erbs, Philippe
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
The invention concerns a polypeptide having a uracil phosphoribosyl transferase (UPRTase) activity derived from a native UPRTase by mutation of one or several residues of said UPRTase. The invention also concerns a nucleotide sequence coding for said UPRTase mutant a vector for expressing the latter, a viral particle and a host cell as well as a composition containing them. The invention further concerns their therapeutic use and a treatment method using them. The invention is particularly useful in the context of therapy by suicide genes in particular for treating proliferative and infectious diseases.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed April 16, 1999 and granted June 5, 2012. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended April 16, 2019.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by April 16, 2021.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.